Quick Summary:
The groundbreaking advancements in the Breakthrough Therapy (BT) Designation market have steadily unfolded a plethora of opportunities in the pharmaceutical industry, necessitating a deep understanding of the market trends to stay ahead in the competitive landscape. Our strategic market research report offers an expansive perspective into the dynamics of the BT Designation market, estimated to reach a substantial volume of US$371.1 Billion by 2030 from its current tally of US$86.3 Billion in 2022.
We meticulously analyze crucial market segments including Oncology, projected to reach an impressive US$125.5 Billion by the conclusion of the analysis period, and the Infectious Diseases segment carrying an adjusted growth potential of 17.3% CAGR for the next eight years. Our report also explores the geographic markets including the U.S., China, Japan, Canada, and Germany, outlining their potential growth rates and expected market sizes.
Our coverage also includes a comprehensive overview of the competitive landscape featuring key players like Abbvie, Acadia, Alexion, and others. Benefit from our online interactive peer-to-peer collaborative bespoke updates and comprehensive access to digital archives and our research platform. We also provide complimentary updates for a year to ensure you stay abreast with the evolving market trends.
Global Breakthrough Therapy (BT) Designation Market to Reach $371.1 Billion by 2030
The global market for Breakthrough Therapy (BT) Designation estimated at US$86.3 Billion in the year 2022, is projected to reach a revised size of US$371.1 Billion by 2030, growing at a CAGR of 20% over the analysis period 2022-2030. Oncology, one of the segments analyzed in the report, is projected to record 21.1% CAGR and reach US$125.5 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Infectious Diseases segment is readjusted to a revised 17.3% CAGR for the next 8-year period.The U.S. Market is Estimated at $25.3 Billion, While China is Forecast to Grow at 19.2% CAGR
The Breakthrough Therapy (BT) Designation market in the U.S. is estimated at US$25.3 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$63.6 Billion by the year 2030 trailing a CAGR of 19.2% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 17.7% and 17% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 14.5% CAGR.Select Competitors (Total 42 Featured) -
- Abbvie
- Acadia
- Alexion
- Amgen
- AstraZeneca
- BMS
- Boehringer Ingelheim
- Eisai
- Eli Lilly
- Exelixis
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and Research Platform
- Complimentary updates for one year
What is the estimated value of the Global Market for Breakthrough Therapy (BT) Designation?
What is the growth rate of the Global Market for Breakthrough Therapy (BT) Designation?
What is the forecasted size of the Global Market for Breakthrough Therapy (BT) Designation?
Who are the key companies in the Global Market for Breakthrough Therapy (BT) Designation?
Report Attribute | Details |
---|---|
No. of Pages | 93 |
Published | September 2023 |
Forecast Period | 2022 - 2030 |
Estimated Market Value ( USD | $ 86.3 Billion |
Forecasted Market Value ( USD | $ 371.1 Billion |
Compound Annual Growth Rate | 20.0% |
Regions Covered | Global |
Table of Contents
Companies Mentioned
A selection of companies mentioned in this report includes:
- Abbvie
- Acadia
- Alexion
- Amgen
- AstraZeneca
- BMS
- Boehringer Ingelheim
- Eisai
- Eli Lilly
- Exelixis